Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.178 EUR | +2.71% |
|
-1.80% | -17.40% |
06-24 | CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board | CI |
05-28 | CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.40% | 763M | - | ||
+19.41% | 45.51B | B- | ||
-8.62% | 38.52B | B | ||
+38.85% | 38.13B | A | ||
+26.95% | 30.74B | B | ||
-13.50% | 26.03B | C | ||
+10.74% | 25.92B | B- | ||
+44.87% | 14.13B | B+ | ||
+34.36% | 12.73B | C+ | ||
-7.14% | 11.29B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CVAC Stock
- 5CV Stock
- Ratings CureVac N.V.